All Updates

All Updates

icon
Filter
Funding
Lycia Therapeutics raises USD 107 million in Series C funding for clinical development of lead therapeutic candidates
Precision Medicine
May 13, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
Precision Medicine

Precision Medicine

May 13, 2024

Lycia Therapeutics raises USD 107 million in Series C funding for clinical development of lead therapeutic candidates

Funding

  • Lycia Therapeutics has raised ~USD 107 million in a Series C funding round led by Venrock Healthcare Capital Partners. with participation from new investors including Janus Henderson Investors, Marshall Wace, Franklin Templeton, as well as existing investors such as Redmile Group, RTW Investments, and Eli Lilly and Company.

  • The company expects to use the funds to advance its lead therapeutic candidates, which focus on autoimmune and inflammatory diseases, into the clinical stage. 

  • Lycia Therapeutics is a biotechnology firm specializing in developing novel therapeutics through its proprietary Lysosomal Targeting Chimera (LYTAC) platform. This platform is designed to degrade extracellular and membrane-bound proteins often implicated in autoimmune disorders and cancers. The company's approach targets undruggable proteins, focusing on autoimmune and inflammatory diseases​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.